Our mission is to improve the quality of human cell culture and research everywhere and become the go-to manufacturer of iPSC-derived cells for all applications. With Life Sciences and Pharmaceutical research still relying on research methods from the 20th century, the stage is set for next-generation human cell models. Celogics’ aim is to make quality human cells that are not just great iPSC-derived cells but the best functional cells for the research subject. We will listen to our users’ needs and provide the high-quality cells they deserve. Our initial product offering will be research-use-only iPSC-derived cell products, under our Celo.Cells brand. These cell products are used in drug discovery, drug safety screening, and disease modeling. We are a newly formed joint venture between Curi Bio (www.curibio.com) & NEXEL (www.nexel.co.kr) and building out a 22,000 square feet facility – reach out and join our exciting project!
| Website | http://www.celogics.com |
| Employees | 2 (2 on RocketReach) |
| Founded | 2021 |
| Address | 222 Fifth Ave N, Seattle, Washington 98109, US |
| Industry | Biotechnology Research |
| Keywords | Induced Pluripotent Stem Cells, Cell Culture, Cell Research, Cellular Research, Life Sciences Research, Cell Manufacturing, Pharmaceutical Research, Biotechnology, Stem Cell Technology, Regenerative Medicine, Pharmaceutical Manufacturing, Biomedical Research, Bioprocessing, Clinical Research |
| Competitors | Epic, Blue Cross Blue Shield Association, Health Catalyst, MassChallenge, Qventus, Inc, MedTech Innovator, Rock Health, StartUp Health, Zebra Medical Vision Ltd, Health 2.0 Nashville +39 more (view full list) |
Looking for a particular Celogics employee's phone or email?
Jin Chang is the CEO of Celogics.
2 people are employed at Celogics.
Celogics is based in Seattle, Washington.